Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management 19th August 2011, ITC Maratha, Sahar, Mumbai, India.
Key Speakers:
Arun Bhatt, President, Clininvent Research Vivek Ahuja, Regional Director, Pharmacovigilance, Baxter Healthcare, Asia Pacific Khalid Saifuddin, Group Head Pharmacovigilance Operations - Drug Safety & Epidemiology, Novartis Moin Don, Executive Director, PVCON Pharmacovigilance Consulting Services Manish R Garg , Country Medical Director, Bayer Simrat Sohal,Clinical Research Physician - Patient safety , Critical Care, Cardiac Care & BHGT, Eli Lilly Khushboo Baxi, Senior Member Pharma Team, Nishith Desai Associates Anurita Majumdar, Medical Director, Eli Lilly
Ramaswamy Valliappan, Pharmacovigilance Expert (PVE) Babita Kirodian, Head-Country Pharmacovigilance, Bristol - Integrated Hospital Care Drug Safety and Epidemiology, Novartis Myers Squibb Parminder Kaur, Managing Director, RegPak BioPharma Consulting (Netherlands) Deven Parmar, Vice President-Clinical Research, Wockhardt Julius Vaz, Senior Vice-President (Global Medical Affairs), Dr.Reddy's Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt Rajani Rokade, Head Pharmacovigilance, Sanofi Aventis Group
Silver Partner
Associate Partner
Supported By
Organized By
2nd Annual Pharmacovigilance 2011 19th August 2011, ITC Maratha, Sahar, Mumbai, India.
Conference Intro:
At the outset, a very cordial and warm invitation is being extended to all who attended the Pharmacovigilance Conference in the year 2010 and its representatives for the Conference to be held in early 2011. The pharmaceutical industry is facing a tough road ahead in the future marketplace. Though pharmaceuticals remain the most cost-effective healthcare intervention, everyone should bring about a significant transformation in their organizations to realize a glorious future. Pharmacovigilance is a scientific and organized study of this subject to unfold, discover, and to evaluate the methods and means of preventing adverse and harmful effects of drugs. Its primary aim is to make use of medicines available in the market for treatment and also prevention of diseases. Some medicines may not suit or agree with some patients due to their physical health condition. Any such harmful effect on patients may bring discredit to the medicines and the industry. A good Pharmacovigilance will easily identify the risk factors in the shortest time so that the harmful effects can be avoided or minimized. In 2009, FDA reported more than 1,742 recall in comparison to 426 in 2008 and fast pace of drug recalls seems to be continuing in 2010 totaled 296 from January through June of this year. According to peer-reviewed published studies, FDA-approved prescription drugs injure 2.2 million and kill approximately 100,000 Americans each year and more realistic estimates put the number of deaths at over 200,000 people annually in the United States alone. Pharmacovigilance 2011 will discuss the pressing concerns confronted with regard to drug safety, addressing the risks, time line, budget constrains, effectively tackling key challenges, overcoming trial agreement and site contract negotiation hurdles. The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. Hence, 2nd Annual Pharmacovigilance 2011 will provide an important platform for Pharmacovigilance stakeholders from India to discuss and share best practices in expediting Pharmacovigilance development in India. It gives me great pleasure in welcoming all of you to the virtue insight's 2nd Annual Pharmacovigilance 2011. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.
2nd Annual Pharmacovigilance 2011 19th August 2011, ITC Maratha, Sahar, Mumbai, India.
08:30 - Coffee and registration - An opportunity to meet and to 11:40 EU Risk Minimisation Plan for Marketing Authorisation Applications network with your conference colleagues. 09:30 - Chairperson opening remarks Vivek Ahuja, Regional Director, Pharmacovigilance, Baxter Healthcare, Asia Pacific (http://in.linkedin.com/pub/vivek-ahuja/16/177/1b9) 09:40 - Analysing the current global PV scene and perspectives of the future Analyzing fundamental statistics & economic concepts of PV under the present market trend Latest PV concepts and applying these methods to drug issues Thought provoking ideas for new methods Consideration of future directions for the PV development Discover how PV will change and adapt from 2011 to 2015
Parminder Kaur, Managing Director, RegPak BioPharma Consulting (Netherlands) (http://nl.linkedin.com/pub/parminderkaur/3/6b2/5b4)
12:20 - Networking luncheon - Take your discussions further & build new relationships in a relaxed & informal setting...
Afternoon Chairperson: Moin Don, Executive Director, PVCON Pharmacovigilance Consulting Services- India
(http://in.linkedin.com/pub/moin-don/2/33a/653)
Vivek Ahuja, Regional Director, Pharmacovigilance, Baxter Healthcare, Asia Pacific (http://in.linkedin.com/pub/vivek-ahuja/16/177/1b9) 10:10 - Topic TBC Speaker TBC, EXTEDO (Germany)
13:30 Economic implication of outsourcing PV India is becoming the most obvious choice for offshore outsourcing of PV activities. Vendors should educate pharmaceutical companies about technology implications and its importance in their day-to-day operations Identifying the key opportunities for biopharmaceutical outsourcing in the area of PV SWOT analysis of India, as an outsourcing target for PV Economic Implications of Top Outsourcing Providers
14:00 Panel Discussion: Why do drugs fail? Pre-approval stages encircling the PV guidelines Analyzing & reviewing the successes and challenges of Phase I and Phase II clinical trials A new medicine must comply with: good quality, effectiveness and safety for the purpose Adverse reaction of drug reporting To initiate follow up on adverse reports about drugs Ongoing risk-benefit assessment during the post-marketing period PV through pre clinical trails and practical approach to PV
Moderator: Vivek Ahuja, Regional Director, Pharmacovigilance, Baxter Healthcare, Asia Pacific (http://in.linkedin.com/pub/vivek-ahuja/16/177/1b9) Panellists: Deepti Sanghavi, Medical Advisor - Clinical research, Wockhardt (http://in.linkedin.com/pub/dr-deepti-sanghavi/5/591/b76) Manish R Garg, Country Medical Director, Bayer
(http://in.linkedin.com/pub/manish-garg-md/a/114/526)
Moderator: Babita Kirodian, Head-Country Pharmacovigilance, Bristol Myers Squibb (http://in.linkedin.com/pub/babita-kirodian/10/736/8bb) Panellists: Deven Parmar, Vice President-Clinical Research, Wockhardt
(http://in.linkedin.com/pub/deven-parmar/15/615/331)
Khalid Saifuddin, Group Head Pharmacovigilance Operations - Drug Safety & Epidemiology, Novartis
(http://in.linkedin.com/in/drkhalidsaifuddin)
2nd Annual Pharmacovigilance 2011 19th August 2011, ITC Maratha, Sahar, Mumbai, India.
14:30 A good PV system - Dependent upon Information 16:30 Developing Pharmacovigilance into high quality management system and its components: Technology (IT) systems Safety signal detection - Merging IT into clinical safety practice Electronic data management & monitoring cost effectively Discover latest technologies and strategies Computer-automated pattern discovery procedures Analysing the recent growth on electronic safety data reporting Discover how software application serves as a warehouse for adverse cases across India Find out the importance of drug safety surveillance that is required to address all relevant quality Communication relating to drug safety and ensuring that they are transparent and able to function efficiently in times of emergency Centralized position to track quality and compliance in line with activities Consistent process to monitor, analyze and resolve incidents
15:00 Afternoon Coffee / Tea 15:20 Panel Discussion: Overcoming regulatory challenges in Asian PV market Today & Tomorrow Improved communication between national drug regulatory authorities and national PV centers and ensuring that regulatory decisions with possible international implications are rapidly communicated to avoid widespread public concern or panic Current PV practices in India and examining various methods to improve PV in Asia Important insights on rapidly evolving PV regulations in the market Strategic challenges in the evolution of Indian PV regulations in next decade Keep abreast with the changing International regulations of PV
Simrat Sohal, Clinical Research Physician - Patient safety, Critical Care, Cardiac Care & BHGT, Eli Lilly
(http://in.linkedin.com/pub/simrat-sohal/10/2a0/614)
17:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting...
Moderator: Moin Don, Executive Director, PVCON Pharmacovigilance Consulting Services- India
(http://in.linkedin.com/pub/moin-don/2/33a/653)
Panellists: Rajani Rokade, Head-Pharmacovigilance, Sanofi Aventis Group Khushboo Baxi, Senior Member Pharma Team, Nishith Desai Associates (http://in.linkedin.com/pub/khushboo-baxi/9/146/391) Anurita Majumdar, Medical Director, Eli Lilly
(http://in.linkedin.com/pub/dr-anurita-majumdar/20/a57/a86)
16:00 Importance and impact of safety signal detection and management in life cycle of a therapeutic drug The need for Signal detection right from developmental phase and continously in the post marketing phase of a drug Adaptive methods in clinical trials for developmental drugs Preparedness for the unexpectedness and addressing the same from developmental phase to post marketing phase Appropriate time for the initiation of postmarketing safety studies Translating the safety information observed with a molecule in the postmarketing phases and translating the same into the clinical trials for the same product in another indication, dosage etc.
Ramaswamy Valliappan, Pharmacovigilance Expert (PVE) Integrated Hospital Care Drug Safety and Epidemiology, Novartis (http://in.linkedin.com/pub/dr-ramaswamy-valliappan/9/a/7b6)
2nd Annual Pharmacovigilance 2011 19th August 2011, ITC Maratha, Sahar, Mumbai, India.
EXHIBITION AREA
10 2 4 6 8
REGISTRATION DESK
10
CORRIDOR
Registration Form 2nd Annual Pharmacovigilance 2011 19th August 2011, ITC Maratha, Sahar, Mumbai, India.
Queries:
Should you have any questions on bookings, Please feel free to contact us.
Payment terms:
Official Contact Number ....................................................... Virtue Insight requires the full amount to be paid before the conference. Virtue Insight may refuse entry to delegates who have not paid their invoice in full.
Address .............................................................................
.............................................................................
Country ...............................Postcode..................................
Email .................................................................................
Indemnity:
Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will refund your registration fee and we will try to reschedule the event.
I confirm that I have read & agree to the terms and conditions of booking..... (Please Tick)
Signature ...........................................................................
News Updates: Please tick if you do not wish to receive email updates in the future
www.virtueinsight.com